Ранняя системная склеродермия -современный алгоритм диагностики (лекция)

1. <div><p>Гусева Н.Г. Системная склеродермия. В кн.: Ревматология. Национальное руководство. М., 2008;447—66.</p><p>Varga J., Abraham D. Systemic sclerosis: a prototypic multisistem fibrotic disorder. J Clin Invest 2007;117:557-67.</p><p>Hunzelmann N., Brinckmann J. What are the milestones in the pathogenesis of systemic sclerosis? Ann Rhеum Dis 2010;69(Suppl. I): i52—i56.</p><p>Гусева Н.Г. Системная склеродермия. В кн.: Я.А. Сигидин, Н.Г. Гусева, М.М. Иванова. Диффузные болезни соединительной ткани. М.: Медицина, 2004;343—487.</p><p>Sakkas L.I., Chikanza I.C., Platsoucas C.D. Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol 2006;2:679-85.</p><p>Abraham D.J., Krieg T., Distler J., Distler O. Overview of pathogenesis of systemic fibrosis. Rheumatology 2009;48(Suppl.):iii3-iii7.</p><p>Wigley F.M., Hummers L.K. Clinical features of systemic sclerosis. In: Rheumatology. Eds: M.C. Hochberg, A.J. Silman, J.S. Smolen et al. 3rd ed. Philadephia: Mosby, 2003;1463—5.</p><p>Medsger T.A. Classification, prognosis. In: Systemic sclerosis. Eds: P.J. Clements, D.E. Furst. 2nd ed. Baltimore: Lippincott Williams&amp;Wilkins, 2004;7—22.</p><p>Scalapino K., Arkachaisri T., Lukas M. et al. Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparasion with adult onset disease. J Rheumatol 2006;33:1004-13.</p><p>Гусева Н.Г. Системная склеродермия и псевдосклеродермические синдромы. М.: Медицина, 1993;13—25.</p><p>Гусева Н.Г. Системная склеродермия: ранняя диагностика и прогноз. Науч-практич ревматол 2007;1:39-46.</p><p>Wollheim F.A. Classification of systemic sclerosis. Vision and reality. Rheumatology 2005;44:1212-6.</p><p>Nihtyanova S.I., Tang E.C., Coghlan J.G. et al. Improved survival in systemic sclerosis in assiciated with better ascertainment of internal organ disease: a retrospective cohort study. QJM 2010;103:109-15.</p><p>Al-Dhaher F.F., Pope J.E., Quimet J.M. Determinants and mortality of systemic sclerosis in Canada. Sem Arthr Rheum 2010;39(4):269—77.</p><p>Hudson M., Thombs B., Baron M. Time to diagnosis in systemic sclerosis: is gender a factor? Arthr Rheum 2007;56(Suppl.):487.</p><p>Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthr Rheum 1980;23:581-90.</p><p>Гусева Н.Г. Феномен Рейно. Справ поликлин врача 2007;15:4-7.</p><p>Алекперов Р.Т. Феномен Рейно. В кн.: Ревматология. Клинические рекомендации. Под ред. Е.Л. Насонова. Изд. 2-е. М.: ГЭОТАР-Медиа, 2010;558-69.</p><p>Алекперов Р.Т., Старовойтова М.Н. Синдром Рейно в практике терапевта. Рус мед журн 2010;18(27):1695—700.</p><p>Hirschl M., Hirschl K., Lenz M. et al. Transition from primary Raynau’s phenomen to secondary Raynaud’s phenomen identified by diagnosis of an associated disease: results of ten years of prospective surveillance. Arthr Rheum 2006;54:1974-81.</p><p>Spenser-Green G. Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. Ann Intern Med 1998;158:595-600.</p><p>Maricq H.R., Gordon G., Le Roy E.C. Studies in patients with connective tissue disorders. Bibl Anat 1977;16(Pt 2):135—41.</p><p>Maricq H.R. Widefield capillary microscopy: Technique and rating scale for abnormalities seen in scleroderma and related disorders. Arthr Rheum 1981;24:1159-65.</p><p>Maricq H.R., Harper F.E., Khan M.M. et al. Microvascular abnormalities as possible predictors of disease subsets in Raynaud phenomenon and early connective tissue disease. Clin Exp Rheumatol 1983;1:195-205.</p><p>Sakkas L.I., Chikanza I.C., Platsoucas C.D. Mechanisms of disease: the role of immune cells in pathogenesis of systemic sclerosis. Nature clinical practice. Rheumatology 2006;2(12):679—84.</p><p>Cepeda E.J., Reveille J.D. Antibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance. Curr Opin Rheumatol 2004;16:723-32.</p><p>Hu P.Q., Fertig N., Medsger T.A. Jr., Wright T.M. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthr Rheum 2003;48:1363-73.</p><p>Steen V.D. Autoantibodies in Sysyemic sclerosis. Sem Arthr Rheum 2005;35:35-42.</p><p>Le Roy E.C., Medsger T.A. Jr. Criteria for classification of early systemic sclerosis. J Rheum 2001;28:1573-6.</p><p>Koenig M., Joyal F., Fritzler M.J. et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: a twenty year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis Arthr Rheum 2008;58:3902-12.</p><p>Matucci-Cerinic M., Allanore Y., Czirjak I. et al. The challenge of early systemic sclerosis for the EULAR Scleroderma Trail and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann Rheum Dis 2009;68:1377-80.</p><p>Avouac J., Fransen J., Walker U.A. et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of Delphi Consensus Study from EULAR Scleroderma Trails and Research Group. Ann Rheun Dis 2011;70:476-81.</p><p>Bournia V.K., Vlachoviannopoulos P.G., Selmi C. et al. Recent advances in the treatment of systemic sclerosis. Clin Rev Allerg Immunol 2009;36(2-3):176-200.</p></div><br />